118
- Otani H, Otsuka F, Inagaki K, Suzuki J, Miyoshi T, Kano Y, et al. Aldosterone break-
through caused by chronic blockage of angiotensin II type 1 receptors in human adrenocor-
tical cells: possible involvement of bone morphogenetic protein-6 actions. Endocrinology.
2008;149(6):2816–25. - Rossi GP. Aldosterone breakthrough during RAS blockade: a role for endothelins and their
antagonists? Curr Hypertens Rep. 2006;8(3):262–8. - Rossi GP, Cavallin M, Nussdorfer GG, Pessina AC. The endothelin-aldosterone axis and
cardiovascular diseases. J Cardiovasc Pharmacol. 2001;38(Suppl 2):S49–52. - Turban S, Wang XY, Knepper MA. Regulation of NHE3, NKCC2, and NCC abundance
in kidney during aldosterone escape phenomenon: role of NO. Am J Physiol Ren Physiol.
2003;285(5):F843–51. - Granger JP, Burnett JC Jr, Romero JC, Opgenorth TJ, Salazar J, Joyce M. Elevated levels of
atrial natriuretic peptide during aldosterone escape. Am J Phys. 1987;252(5 Pt 2):R878–82. - Wang C, Chao J, Chao L. Adenovirus-mediated human prostasin gene delivery is linked to
increased aldosterone production and hypertension in rats. Am J Physiol Regul Integr Comp
Physiol. 2003;284(4):R1031–6. - Raizada V, Skipper B, Luo W, Griffith J. Intracardiac and intrarenal renin-angiotensin sys-
tems: mechanisms of cardiovascular and renal effects. J Invest Med Off Publ Am Fed Clin
Res. 2007;55(7):341–59. - Grubler MR, Kienreich K, Gaksch M, Verheyen N, Hartaigh BO, Fahrleitner-Pammer A,
et al. Aldosterone-to-renin ratio is associated with reduced 24-hour heart rate variability and
QTc prolongation in hypertensive patients. Medicine. 2016;95(8):e2794. - Stowasser M. Aldosterone excess and resistant hypertension: investigation and treatment.
Curr Hypertens Rep. 2014;16(7):439. - Sartori M, Calo LA, Mascagna V, Realdi A, Macchini L, Ciccariello L, et al. Aldosterone
and refractory hypertension: a prospective cohort study. Am J Hypertens. 2006;19(4):373–9;
discussion 380. - Shibata H, Itoh H. Mineralocorticoid receptor-associated hypertension and its organ damage:
clinical relevance for resistant hypertension. Am J Hypertens. 2012;25(5):514–23. - Semplicini A, Strapazzon G, Papparella I, Sartori M, Realdi A, Macchini L, et al. RGS2
expression and aldosterone: renin ratio modulate response to drug therapy in hypertensive
patients. J Hypertens. 2010;28(5):1104–8. - Gaddam KK, Nishizaka MK, Pratt-Ubunama MN, Pimenta E, Aban I, Oparil S, et al.
Characterization of resistant hypertension: association between resistant hyperten-
sion, aldosterone, and persistent intravascular volume expansion. Arch Intern Med.
2008;168(11):1159–64. - Ames MK, Atkins CE, Lantis AC, Zum Brunnen J. Evaluation of subacute change in RAAS
activity (as indicated by urinary aldosterone:creatinine, after pharmacologic provocation) and
the response to ACE inhibition. J Renin Angiotensin Aldosterone Syst JRAAS. 2016;17(1).
http://journals.sagepub.com/doi/abs/10.1177/1470320316633897?url_ver=Z39.88-
2003&rfr_id=ori%3Arid%3Acrossref.org&rfr_dat=cr_pub%3Dpubmed - Ichihara A. (pro)renin receptor and vacuolar H(+)-ATPase. Keio J Med. 2012;61(3):73–8.
- Oshima Y, Morimoto S, Ichihara A. Roles of the (pro)renin receptor in the kidney. World
J Nephrol. 2014;3(4):302–7. - Shi P, Grobe JL, Desland FA, Zhou G, Shen XZ, Shan Z, et al. Direct pro-inflammatory
effects of prorenin on microglia. PLoS One. 2014;9(10):e92937. - Nguyen G. Renin and prorenin receptor in hypertension: what’s new? Curr Hypertens Rep.
2011;13(1):79–85. - Prieto MC, Botros FT, Kavanagh K, Navar LG. Prorenin receptor in distal nephron segments
of 2-kidney, 1-clip goldblatt hypertensive rats. Ochsner J. 2013;13(1):26–32. - Ando T, Ichihara A. Novel approach to cardiovascular diseases: a promising probability of
(pro)renin receptor [(P)RR]. Curr Pharm Des. 2014;20(14):2371–6. - Gonzalez AA, Womack JP, Liu L, Seth DM, Prieto MC. Angiotensin II increases the expres-
sion of (pro)renin receptor during low-salt conditions. Am J Med Sci. 2014;348(5):416–22.
A. Burlacu and A. Covic